Shanghai Kaibao Pharmaceutical Co Ltd
300039
Company Profile
Business description
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
Contact
88 Chengpu Road
Shanghai Industrial Comprehensive Development Zone
Shanghai201401
CHNT: +86 2137572030
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,225
Stocks News & Analysis
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.50 | 11.90 | -0.13% |
| CAC 40 | 7,861.96 | 4.60 | 0.06% |
| DAX 40 | 24,262.22 | 44.85 | 0.19% |
| Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
| FTSE 100 | 9,136.94 | 0.62 | 0.01% |
| HKSE | 24,906.39 | 270.54 | -1.07% |
| NASDAQ | 21,129.67 | 31.38 | 0.15% |
| Nikkei 225 | 41,020.79 | 366.09 | 0.90% |
| NZX 50 Index | 12,836.39 | 19.58 | -0.15% |
| S&P 500 | 6,362.90 | 7.96 | -0.12% |
| S&P/ASX 200 | 8,749.30 | 7.10 | -0.08% |
| SSE Composite Index | 3,591.26 | 24.46 | -0.68% |